Immuno-oncology
Reimagined
Extrinsic Immunity Therapeutics, LLC is pioneering a new era of targeted oncology therapeutics and diagnostic tools by leveraging NET technology. Neutrophil extracellular traps (NETs), a crucial immune material released by white blood cells during infections, play a paradoxical role in cancer. While they support our immune system, NETs also fuel tumor growth and metastasis. By specifically targeting NETs, we aim to sever the lifeline of tumors and hinder their progression.
Located in the vibrant heart of Ann Arbor, Michigan, our company is driven by leading biomedical researchers, clinicians, and breast cancer surgeons. Our mission is unwavering: to support patients through relentless innovation. Our extensive commercialization portfolio reflects this commitment.
We are proud to collaborate with esteemed partners such as Nucleate, SPARK, Wacker Chemical, the American Cancer Society, and the University of Michigan. Discover what sets us apart and join us in our mission to revolutionize cancer treatment.
NETrolyze is a neoadjuvant slow-release immunotherapy injected directly into and around a triple-negative breast cancer tumor. Its enduring formulation hinders the immune material that has been shown to promote metastasis by locally denaturing these proteins.
A first-in-class immunotherapy to prevent or delay metastasis
Harness NETs as an adjuvant to increase vaccine efficacy.
AdjuvNET is a patterned multi-well plate that creates a simple, standardized method to optimally prime dendritic cells ex vivo during vaccine preparation. Using our patented NET-like biomaterial, AdjuvNET can elicit an enhanced adaptive immune response.
330 Liberty St, Ann Arbor, MI 48104